In this Supplement
How drug-eluting therapies are shaping a new era of endovascular interventions.
A discussion of potential differential indications for drug-eluting devices.
By Prof. Thomas Zeller, MD
Translational findings from the Ranger Paclitaxel-Coated Balloon data.
By Renu Virmani, MD, FACC
Renu Virmani, MD
President CV Path Institute
See Dr. Renu Virmani and Dr. Juan Granada discuss the future of drug-eluting technologies
The Science Behind Local Drug-Delivery Technologies: The Benefit of Sustained Paclitaxel Release in the SFA
Sustained drug release is key to maintaining biological effect.
By Juan F. Granada, MD, FACC
Juan Granada, MD
Executive Director CRF Skirball Center for Innovation
See Dr. Juan Granada discuss the importance of sustained drug release
With Michael R. Jaff, DO
Recent early data from two studies demonstrate the promise of the Ranger DCB.
Is the drug-eluting vascular stent a game-changer?
By Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA
A discussion of DCB durability and superiority in the context of 2-year data.